Azithromycin (ophthalmic) clinical studies: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
 
(4 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Azithromycin}}
{{Azithromycin (ophthalmic)}}
{{CMG}}
{{CMG}}; {{AE}} {{SS}}


==Clinical Studies==
==Clinical Studies==


===Community-Acquired Pneumonia===
In a randomized, vehicle-controlled, double-blind, multicenter clinical study in which patients were dosed twice daily for the first two days, then once daily on days 3, 4, and 5, AzaSite solution was superior to vehicle on days 6-7 in patients who had a confirmed clinical diagnosis of bacterial conjunctivitis. Clinical resolution was achieved in 63% (82/130) of patients treated with AzaSite versus 50% (74/149) of patients treated with vehicle. The p-value for the comparison was 0.03 and the 95% confidence interval around the 13% (63%-50%) difference was 2% to 25%. The microbiological success rate for the eradication of the baseline pathogens was approximately 88% compared to 66% of patients treated with vehicle (p<0.001, confidence interval around the 22% difference was 13% to 31%). Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  |title = AZASITE (AZITHROMYCIN) SOLUTION [INSPIRE PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dc0f75a-1e14-469f-af4f-c668a32f2328 |publisher =  | date =  | accessdate = }}</ref>
 
In a controlled study of community-acquired pneumonia performed in the U.S., azithromycin (500 mg as a single daily dose by the intravenous route for 2–5 days, followed by 500 mg/day by the oral route to complete 7–10 days therapy) was compared to cefuroxime (2250 mg/day in three divided doses by the intravenous route for 2–5 days followed by 1000 mg/day in two divided doses by the oral route to complete 7–10 days therapy), with or without erythromycin. For the 291 patients who were evaluable for clinical efficacy, the clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 277 patients seen at 10–14 days post-therapy were as follows:
 
{|
|-
|[[File:Azithromycin 8.jpg|thumb|800px|left]]
|-
|}
 
In a separate, uncontrolled clinical and microbiological trial performed in the U.S., 94 patients with community-acquired pneumonia who received azithromycin in the same regimen were evaluable for clinical efficacy. The clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 84 patients seen at 10–14 days post-therapy were as follows:
 
{|
|-
|[[File:Azithromycin 9.jpg|thumb|800px|left]]
|-
|}
 
Microbiological determinations in both trials were made at the pre-treatment visit and, where applicable, were reassessed at later visits. Serological testing was done on baseline and final visit specimens. The following combined presumptive bacteriological eradication rates were obtained from the evaluable groups:
 
Combined Bacteriological Eradication Rates for Azithromycin:
 
{|
|-
|[[File:Azithromycin 10.jpg|thumb|800px|left]]
|-
|}
 
The presumed bacteriological outcomes at 10–14 days post-therapy for patients treated with azithromycin with evidence (serology and/or culture) of atypical pathogens for both trials were as follows:
 
{|
|-
|[[File:Azithromycin 11.jpg|thumb|800px|left]]
|-
|}


==References==
==References==

Latest revision as of 21:50, 5 January 2014

Azithromycin (ophthalmic)
AZASITE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Clinical Studies

In a randomized, vehicle-controlled, double-blind, multicenter clinical study in which patients were dosed twice daily for the first two days, then once daily on days 3, 4, and 5, AzaSite solution was superior to vehicle on days 6-7 in patients who had a confirmed clinical diagnosis of bacterial conjunctivitis. Clinical resolution was achieved in 63% (82/130) of patients treated with AzaSite versus 50% (74/149) of patients treated with vehicle. The p-value for the comparison was 0.03 and the 95% confidence interval around the 13% (63%-50%) difference was 2% to 25%. The microbiological success rate for the eradication of the baseline pathogens was approximately 88% compared to 66% of patients treated with vehicle (p<0.001, confidence interval around the 22% difference was 13% to 31%). Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.[1]

References

  1. ↑ "AZASITE (AZITHROMYCIN) SOLUTION [INSPIRE PHARMACEUTICALS, INC.]".

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Azithromycin_(ophthalmic)_clinical_studies&oldid=924966"